Figure 3.

Clinical implications of MK hyperplasia. MK hyperplasia can be seen in many clinical status including clonal hematopoiesis (CH) and myeloproliferative neoplasm (MPN). Mutations in genes that cause CH or MPN are found more frequently in the elderly population. Cancers are another critical risk for thrombocytosis and platelet activation. MK hyperplasia results in either thrombocytosis (increased platelet count) or thrombocytopenia (decreased platelet count), presumably depending on physiological relevance of megakaryopoiesis as well as fibrotic status in the bone marrow. Alterations in platelet number can be implicated to increased risks of thrombus formation and/or platelet disorders.